This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giaccone, G. Articles by Moody, T. W. Search for Related Content PubMed PubMed Citation Articles by Giaccone, G. Articles by Moody, T. W.

Neuromedin B Is Present in Lung Cancer Cell Lines¹

NCI-Navy Medical Oncology Branch, National Cancer Institute and Naval Hospital, Bethesda, Maryland 20889 [G. G., A. F. G., H. O.]; Laboratory of Neurochemistry, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland 20892 [J. B.]; and Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC 20037 [M. D., T. W. M.]

Previously, high levels of gastrin-releasing peptide and its mRNA were detected in classic small cell lung cancer cell lines. Here the ability of lung cancer cell lines to synthesize neuromedin B (NMB), a structurally similar mammalian bombesin-like peptide, was investigated. By radio-immunoassay, NMB (0.1–0.7 pmol/mg of protein) was detected in 23 of 33 lung cancer cell lines. In contrast, gastrin-releasing peptide (0.1–12.9 pmol/mg of protein) was detected in 16 of 32 cell lines. Using gel filtration and high pressure liquid chromatography techniques, the main peak of immunoreactive NMB coeluted with synthetic NMB. By Northern analysis, a 0.8-kilobase mRNA species was present, using poly(A) mRNA derived from two of three lung cancer cell lines. Using a more sensitive S1 nuclease protection assay, NMB mRNA was present in most of the 15 lung cancer cell lines examined. These data suggest that NMB may be a regulatory peptide in lung cancer.

This article has been cited by other articles:

				P. S. Reddy, K. D. Burroughs, L. M. Hales, S. Ganesh, B. H. Jones, N. Idamakanti, C. Hay, S. S. Li, K. L. Skele, A.-J. Vasko, et al. Seneca Valley Virus, a Systemically Deliverable Oncolytic Picornavirus, and the Treatment of Neuroendocrine Cancers J Natl Cancer Inst, November 7, 2007; 99(21): 1623 - 1633. [Abstract] [Full Text] [PDF]